Massimo Aglietta
Overview
Explore the profile of Massimo Aglietta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
244
Citations
6478
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Circosta P, Donini C, Gallo S, Giraudo L, Gammaitoni L, Rotolo R, et al.
Br J Haematol
. 2022 Sep;
200(1):64-69.
PMID: 36155897
Cytokine-induced killer lymphocytes (CIK) are a promising alternative to conventional donor lymphocyte infusion (DLI), following allogeneic haematopoietic cell transplantation (HCT), due to their intrinsic anti-tumour activity and reduced risk of...
12.
Fiorino E, Merlini A, DAmbrosio L, Cerviere I, Berrino E, Marchio C, et al.
Int J Mol Sci
. 2022 Sep;
23(18).
PMID: 36142281
Gastrointestinal stromal tumors (GISTs) are rare, mesenchymal tumors of the gastrointestinal tract, characterized by either KIT or PDGFRA mutation in about 85% of cases. KIT/PDGFRA wild type gastrointestinal stromal tumors...
13.
Merlini A, Centomo M, Ferrero G, Chiabotto G, Miglio U, Berrino E, et al.
Front Oncol
. 2022 Sep;
12:844250.
PMID: 36110934
Background: Advanced and unresectable bone and soft tissue sarcomas (BSTS) still represent an unmet medical need. We demonstrated that the alkylating agent trabectedin and the PARP1-inhibitor olaparib display antitumor activity...
14.
Rossini D, Antoniotti C, Lonardi S, Pietrantonio F, Moretto R, Antonuzzo L, et al.
J Clin Oncol
. 2022 Jun;
40(25):2878-2888.
PMID: 35666229
Purpose: To verify whether the intensification of the upfront chemotherapy backbone with a modified schedule of modified fluorouracil, leucovorin, oxaliplatin, and irinotecan (mFOLFOXIRI) increases the activity of fluorouracil, leucovorin, and...
15.
Berrino E, Filippi R, Visintin C, Peirone S, Fenocchio E, Farinea G, et al.
NPJ Precis Oncol
. 2022 Mar;
6(1):15.
PMID: 35260767
The onset of multiple and metachronous tumors in young patients induces to suspect the presence of genetic variants in genes associated with tumorigenesis. We describe here the unusual case of...
16.
Massa A, Peraldo-Neia C, Vita F, Varamo C, Basirico M, Raggi C, et al.
Front Oncol
. 2022 Mar;
12:771418.
PMID: 35251961
The treatment of unresectable cholangiocarcinoma (CCA) is limited by the development of resistance to conventional first-line chemotherapy based on gemcitabine (GEM). In addition, a prior treatment with GEM frequently induces...
17.
Nepote A, Avallone G, Ribero S, Cavallo F, Roccuzzo G, Mastorino L, et al.
J Clin Med
. 2022 Feb;
11(3).
PMID: 35160279
About 50% of melanomas harbour a BRAF mutation. Of these 50%, 10% have a V600K mutation. Although it is the second most common driver mutation after V600E, no specific studies...
18.
Rimini M, Casadei-Gardini A, Brandi G, Leone F, Fornaro L, Pella N, et al.
J Chemother
. 2022 Feb;
34(8):543-549.
PMID: 35156913
Biliary tract cancer's (BTC) treatment main stone for advanced stages is constituted by chemotherapy. Surgical centralization and physicians' confidence in the use of new technologies and molecular analysis turned out...
19.
Pignochino Y, Crisafulli G, Giordano G, Merlini A, Berrino E, Centomo M, et al.
Cancers (Basel)
. 2021 Dec;
13(24).
PMID: 34944915
Drug-induced tumor mutational burden (TMB) may contribute to unleashing the immune response in relatively "immune-cold" tumors, such as sarcomas. We previously showed that PARP1 inhibition perpetuates the DNA damage induced...
20.
Giordano G, Merlini A, Ferrero G, Mesiano G, Fiorino E, Brusco S, et al.
Cells
. 2021 Nov;
10(11).
PMID: 34831119
Bone sarcomas are a group of heterogeneous malignant mesenchymal tumors. Complete surgical resection is still the cornerstone of treatment, but, in the advanced/unresectable setting, their management remains challenging and not...